Sort   by:  
 Page size 
MetabolomicsFuzheng Jiedu Xiaoji Formula Enhances Anti-PD-1 Therapy for Hepatocellular Carcinoma by Inhibiting Regulatory T Cell Lipotoxicity

Background: The objective response rate of anti-programmed death receptor 1 (PD-1) immunotherapy in hepatocellular carcinoma (HCC) remains limited. The tumor immunosuppressive microenvironment mediated by regulatory T cells (Tregs) is a key bottleneck. The traditional Chinese medicine (TCM) compo...

2025-12-05 | MTBLS13458 | MetaboLights
MetabolomicsFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights
MetabolomicsChanges in L-phenylalanine concentration reflect and predict response to anti-PD-1 treatment combined with chemotherapy in patients with non-small cell lung cancer
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights
TranscriptomicsSingle-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients
We evaluated blood samples from 6 patients with metastatic melanoma treated with anti-LAG3+anti-PD1 (160+480 mg) in a phase I trial (NCT01968109) using single-cell RNA and T cell receptor (TCR) sequencing (scRNA+TCRαβ-seq, 10X 5') combined with other multiomics profiling (flow, cytokine, TCRb-seq) f...
ORGANISM(S): Homo sapiens 
2023-02-03 | E-MTAB-12733 | biostudies-arrayexpress
ProteomicsProteomic profiling to predict therapeutic response to anti-PD1 therapy in advanced melanoma – Orbitrap Elite dataset depleted serum
MS-based proteomics based on data-dependent acquisition / shotgun MS was used to study the response of melanoma patients to anti-PD1 therapy. Human serum samples were collected from patients at the start of their therapy and later categorized into responders and non-responders based on clinical outc...
ORGANISM(S): Homo sapiens (Human) 
2023-08-18 | PXD027849 | Pride
Melanoma  serum  immunodepletion  drug response  therapeutic efficacy  anti-pd1 therapy  biomarker discovery 
ProteomicsProteomic profiling to predict therapeutic response to anti-PD1 therapy in advanced melanoma – SWATH MS dataset - glycopeptides
MS-based proteomics based on data-independent acquisition / SWATH MS was used to study the response of melanoma patients to anti-PD1 therapy. Human serum samples were collected from patients at the start of their therapy and later categorized into responders and non-responders based on clinical outc...
ORGANISM(S): Homo sapiens (Human) 
2023-08-21 | PXD027933 | Pride
Melanoma  serum  immunodepletion  drug response  therapeutic efficacy  anti-pd1 therapy  biomarker discovery 
ProteomicsHigh-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models
Introduction: Immune checkpoint inhibitors(ICIs) targeting programmed cell death protein 1 (PD1) confer significant survival benefits to patients with non-small cell lung cancer (NSCLC). However, there remains a substantial unmet need to identify therapeutic approaches to overcome resistance and pr...
ORGANISM(S): Mus musculus (Mouse) 
2025-01-15 | PXD059688 | Pride
Lc-msms Mouse Lung cancer 
GenomicsOver-expression of GUSB leads to primary resistance of anti-PD1 therapy in hepatocellular carcinoma
Over-expression of GUSB leads to primary resistance of anti-PD1 therapy in hepatocellular carcinoma
PRJNA814103 | ENA
ProteomicsProteomics of serum extracellular vesicles from patients with advanced melanoma treated with anti-PD1 inhibitors
Protein content of extracellular vesicles from serun of advanced melanoma patients treated with anti-PD1 therapy.
ORGANISM(S): Homo sapiens (Human) 
2026-02-23 | PXD062378 | Pride
Pd1 Extracellular vesicles Melanoma 
ProteomicsProteomics of the Gastric cancer Response to anti-PD1 therapy
To validate the correlation between Th1/Th2 ratio and immunotherapeutic effectiveness, we collected a group of GC patients treated with anti-PD1 therapy, including 7 responder cases (PR) and 7 non-responder cases (SD/PD). The formalin-fixed paraffin-embedded (FFPE) tumor tissue sections derived from...
ORGANISM(S): Homo Sapiens 
2022-11-17 | PXD038188 |
Sort   by:  
 Page size